513 related articles for article (PubMed ID: 22268099)
1. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
3. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
[TBL] [Abstract][Full Text] [Related]
4. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
6. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice.
Begriche K; Lettéron P; Abbey-Toby A; Vadrot N; Robin MA; Bado A; Pessayre D; Fromenty B
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E939-51. PubMed ID: 18349116
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
[TBL] [Abstract][Full Text] [Related]
9. A mouse model for nonalcoholic steatohepatitis.
Sundaresan S; Vijayagopal P; Mills N; Imrhan V; Prasad C
J Nutr Biochem; 2011 Oct; 22(10):979-84. PubMed ID: 21190824
[TBL] [Abstract][Full Text] [Related]
10. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
12. Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis.
Kawaguchi T; Itou M; Taniguchi E; Sata M
Int J Mol Med; 2014 Sep; 34(3):782-7. PubMed ID: 24993337
[TBL] [Abstract][Full Text] [Related]
13. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
14. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling.
Imajo K; Fujita K; Yoneda M; Nozaki Y; Ogawa Y; Shinohara Y; Kato S; Mawatari H; Shibata W; Kitani H; Ikejima K; Kirikoshi H; Nakajima N; Saito S; Maeyama S; Watanabe S; Wada K; Nakajima A
Cell Metab; 2012 Jul; 16(1):44-54. PubMed ID: 22768838
[TBL] [Abstract][Full Text] [Related]
15. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
[TBL] [Abstract][Full Text] [Related]
16. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
Tomas E; Wood JA; Stanojevic V; Habener JF
Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
18. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet.
Matsuzawa N; Takamura T; Kurita S; Misu H; Ota T; Ando H; Yokoyama M; Honda M; Zen Y; Nakanuma Y; Miyamoto K; Kaneko S
Hepatology; 2007 Nov; 46(5):1392-403. PubMed ID: 17929294
[TBL] [Abstract][Full Text] [Related]
19. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]